Corcept Therapeutics Stock Income Statements

Corcept Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Corcept Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-05-13	2011-09-30	2011-05-13	2011-05-13	2010-12-31	2010-05-13	2010-03-31	2009-12-31	2009-06-30	2009-05-13	2008-12-31	2008-09-30	2008-05-13	2008-03-31	2007-12-31	2007-06-30	2007-05-13	2007-03-31	2006-12-31	2006-09-30	2006-05-13	2005-09-30	2005-06-30	2005-05-13	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31

product revenue	194,430,000	157,214,000	181,890,000	182,546,000	163,796,000	146,808,000	135,405,000	123,601,000	117,715,000	105,654,000	103,056,000	101,728,000	103,386,000	93,688,000	98,822,000	96,131,000	91,588,000	79,437,000	85,735,000	86,327,000	88,565,000	93,247,000	87,895,000	81,505,000	72,257,000	64,829,000	66,831,000	64,445,000	62,312,000	57,659,000	53,280,000	42,763,000	35,559,000	27,599,000	23,812,000	21,725,000	19,724,000	16,061,000	8,829,750	13,261,000	11,956,000	10,102,000
operating expenses:
cost of sales	3,433,000	2,403,000	2,956,000	2,867,000	2,524,000	2,535,000	1,877,000	1,645,000	1,574,000	1,386,000	1,480,000	1,339,000	1,316,000	1,250,000	1,354,000	1,275,000	1,384,000	1,268,000	1,254,000	1,216,000	1,234,000	1,878,000	1,436,000	1,451,000	1,377,000	1,240,000	-3,635,741	1,308,000	1,154,000	1,174,000	1,157,000	976,000	775,000	646,000	561,000	668,000	426,000	403,000	364,000	256,000	439,000	302,000	258,000	235,000	215,000	174,000	61,000	40,000	23,000	20,000	19,000	24,000	48,000
gross profit
yoy
qoq
gross margin %
research and development	60,471,000	60,735,000	70,300,000	59,336,000	58,745,000	58,505,000	54,707,000	45,517,000	43,277,000	40,851,000	36,754,000	33,292,000	32,825,000	28,120,000	28,519,000	28,091,000	28,232,000	29,022,000	28,275,000	33,869,000	26,497,000	26,123,000	24,312,000	22,805,000	21,656,000	20,244,000	-56,445,988	18,860,000	20,543,000	17,050,000	13,631,000	11,693,000	7,876,000	7,176,000	6,484,000	7,054,000	5,672,000	4,634,000	-11,329,161	3,612,000	3,341,000	4,377,000	-14,582,277	3,047,000	4,252,000	7,285,000	6,567,000	5,155,000	4,491,000	4,257,000	4,856,000	3,008,000	2,668,000	3,542,000	110			5,433	5,401	63	5,208	68	5,211	4,811	70	4,876	64	4,688	56	4,680	29	4,076	103	4,348	53	-194	3,922	74	84,773	-140,481	117,140	141,002
selling, general and administrative	103,851,000	90,660,000	83,372,000	73,745,000	66,935,000	56,268,000	47,152,000	45,262,000	43,281,000	48,564,000	42,323,000	35,163,000	37,813,000	37,549,000	32,285,000	30,533,000	30,029,000	29,509,000	25,696,000	26,523,000	25,572,000	27,535,000	27,131,000	24,245,000	24,591,000	24,389,000	-59,712,524	21,308,000	19,981,000	18,440,000	16,795,000	16,471,000	14,113,000	15,037,000	11,760,000	10,931,000	12,118,000	10,432,000	-28,080,826	9,291,000	9,342,000	9,453,000	-26,867,522	9,103,000	7,965,000	9,805,000	7,517,000	7,179,000	8,160,000	8,383,000	6,482,000	5,694,000	5,751,000	7,487,000
total operating expenses	167,755,000	153,798,000	156,628,000	135,948,000	128,204,000	117,308,000	103,736,000	92,424,000	88,132,000	90,801,000	80,557,000	69,794,000	71,954,000	66,919,000	62,158,000	59,899,000	59,645,000	59,799,000	55,225,000	61,608,000	53,303,000	55,536,000	52,879,000	48,501,000	47,624,000	45,873,000	41,933,000	41,476,000	41,678,000	36,664,000	31,583,000	29,140,000	22,764,000	22,859,000	18,805,000	18,653,000	18,216,000	15,469,000	13,316,000	13,159,000	13,122,000	14,132,000	12,091,000	12,385,000	12,432,000	17,264,000	14,145,000	12,374,000	12,674,000	12,660,000	11,357,000	8,726,000	8,467,000	11,029,000	6,437,000			175,965,000	167,482,000	6,064,000	150,085,000	4,888,000	149,810,000	120,956,000	4,968,000	123,566,000	4,083,000	112,844,000	1,953,000	110,378,000	2,736,000	80,258,000	6,549,000	91,458,000	5,481,000	4,386,000	70,407,000	5,787,000	5,522,394	4,257,966	3,694,446	2,570,029
income from operations	26,675,000	3,416,000	25,262,000	46,598,000	35,592,000	29,500,000	31,669,000	31,177,000	29,583,000	14,853,000	22,499,000	31,934,000	31,432,000	26,769,000	36,664,000	36,232,000	31,943,000	19,638,000	30,510,000	24,719,000	35,262,000	37,711,000	35,016,000	33,004,000	24,633,000	18,956,000	24,898,000	22,969,000	20,634,000	20,995,000	21,697,000	13,623,000	12,795,000	4,740,000	5,007,000	3,072,000	1,508,000	592,000	1,651,000	102,000	-1,166,000	-4,030,000	-3,077,000	-5,103,000	-6,581,000	-12,859,000	-10,030,000	-9,740,000	-10,783,000	-10,943,000	-9,980,000	-7,671,000	-7,592,000	-11,029,000	-6,437,000			-174,951,000	-166,468,000	-6,064,000	-149,077,000	-4,882,000	-148,796,000	-120,037,000	-4,902,000	-122,790,000	-4,083,000	-112,442,000	-1,579,000	-109,602,000	-2,628,000	-80,185,000	-6,549,000	-91,237,000
yoy	-25.05%	-88.42%	-20.23%	49.46%	20.31%	98.61%	40.76%	-2.37%	-5.88%	-44.51%	-38.63%	-11.86%	-1.60%	36.31%	20.17%	46.58%	-9.41%	-47.93%	-12.87%	-25.10%	43.15%	98.94%	40.64%	43.69%	19.38%	-9.71%	14.75%	68.60%	61.27%	342.93%	333.33%	343.46%	748.47%	700.68%	203.27%	2911.76%	-229.33%	-114.69%	-153.66%	-102.00%	-82.28%	-68.66%	-69.32%	-47.61%	-38.97%	17.51%	0.50%	26.97%	42.03%	-0.78%	55.04%	-104.05%	-104.01%	-93.70%	-96.13%	-227.12%	-227.12%	3483.59%	11.88%	-94.95%	2941.15%	-96.02%	3544.28%	6.75%	210.45%	12.03%	55.37%	40.23%	-75.89%	20.13%
qoq	680.88%	-86.48%	-45.79%	30.92%	20.65%	-6.85%	1.58%	5.39%	99.17%	-33.98%	-29.55%	1.60%	17.42%	-26.99%	1.19%	13.43%	62.66%	-35.63%	23.43%	-29.90%	-6.49%	7.70%	6.10%	33.98%	29.95%	-23.87%	8.40%	11.32%	-1.72%	-3.24%	59.27%	6.47%	169.94%	-5.33%	62.99%	103.71%	154.73%	-64.14%	1518.63%	-108.75%	-71.07%	30.97%	-39.70%	-22.46%	-48.82%	28.21%	2.98%	-9.67%	-1.46%	9.65%	30.10%	1.04%	-31.16%	71.34%	-103.40%	-208.32%	-208.32%	5.10%	2645.18%	-95.93%	2953.61%	-96.72%	23.96%	2348.74%	-96.01%	2907.35%	-96.37%	7021.09%	-98.56%	4070.55%	-96.72%	1124.39%	-92.82%
operating margin %
interest and other income	5,017,000	6,202,000	6,698,000	6,345,000	6,004,000	5,493,000	5,140,000	5,208,000	3,347,000	3,581,000	1,777,000	1,070,000	630,000	80,000	72,000	72,000	110,000	275,000	297,000	622,000	1,010,000	1,471,000	1,444,000	1,348,000	1,178,000	1,097,000	403,750	759,000	562,000	294,000	188,000	86,000	-98,000	-225,000	-410,000	-487,000	-531,000	-611,000	-568,250	-703,000	-770,000	-800,000	-736,500	-903,000	-971,000	-1,071,000	-855,250	-1,166,000	-1,114,000	-1,141,000					3,000	5,551	5,551	6,819,000	5,332,000	2,000	5,320,000	6,000	5,322,000	4,478,000	291,000	4,737,000	157,000	4,118,000	164,000	4,047,000	96,000	2,985,000	154,000	3,329,000	278,000	282,000	2,591,000	283,000	268,816	169,201	115,913	24,308
income before income taxes	31,692,000	9,618,000	31,960,000	52,943,000	41,596,000	34,993,000	36,809,000	36,385,000	32,930,000	18,434,000	24,276,000	33,004,000	32,062,000	26,849,000	36,736,000	36,304,000	32,053,000	19,913,000	30,807,000	25,341,000	36,272,000	39,182,000	36,460,000	34,352,000	25,811,000	20,053,000	25,940,000	23,728,000	21,196,000	21,289,000	21,885,000	13,709,000	12,697,000	4,515,000
income tax benefit	3,457,000	10,929,000					-3,240,750	-5,007,000			-1,774,500	1,604,000		-4,052,000				3,552,000									29,554,000	-5,981,000			76,445,000	48,000																								189,507,000	189,507,000
net income	35,149,000	20,547,000	30,746,000	47,213,000	35,488,000	27,762,000	31,355,000	31,378,000	27,528,000	15,879,000	16,601,000	34,608,000	27,412,000	22,797,000	32,053,000	30,471,000	26,523,000	23,465,000	25,994,000	21,625,000	28,327,000	30,065,000	29,381,000	26,340,000	20,186,000	18,274,000	22,008,000	17,747,000	18,196,000	17,459,000	98,330,000	13,757,000	12,647,000	4,388,000																						-3225.12%	-3225.12%	-170,509,000	-162,006,000	-6,073,000	-145,360,000	-4,878,000	-145,068,000	-116,182,000	-5,565,000	-118,336,000	-3,930,000	-108,594,000	-1,417,000	-105,818,000	-2,535,000	-77,442,000	-6,403,000	-88,159,000	-5,223,000	-4,111,000	-68,053,000	-5,512,000	-5,311,046	-4,088,765	-3,583,741	-2,550,929
yoy	-0.96%	-25.99%	-1.94%	50.47%	28.92%	74.83%	88.87%	-9.33%	0.42%	-30.35%	-48.21%	13.58%	3.35%	-2.85%	23.31%	40.91%	-6.37%	-21.95%	-11.53%	-17.90%	40.33%	64.52%	33.50%	48.42%	10.94%	4.67%	-77.62%	29.00%	43.88%	297.88%																												3395.47%	11.68%	-94.77%	2512.04%	-95.88%	3591.30%	6.99%	292.73%	11.83%	55.03%	40.23%	-77.87%	20.03%	-51.46%	1783.78%	-90.59%	1499.40%	-1.66%	0.54%	1798.94%	116.08%
qoq	71.07%	-33.17%	-34.88%	33.04%	27.83%	-11.46%	-0.07%	13.99%	73.36%	-4.35%	-52.03%	26.25%	20.24%	-28.88%	5.19%	14.89%	13.03%	-9.73%	20.20%	-23.66%	-5.78%	2.33%	11.55%	30.49%	10.46%	-16.97%	24.01%	-2.47%	4.22%	-82.24%	614.76%	8.78%	188.22%																									5.25%	2567.64%	-95.82%	2879.91%	-96.64%	24.86%	1987.73%	-95.30%	2911.09%	-96.38%	7563.66%	-98.66%	4074.28%	-96.73%	1109.46%	-92.74%	1587.90%	27.05%	-93.96%	1134.63%	3.78%	29.89%	14.09%	40.49%
net income margin %
net income attributable to common stockholders	34,611,000	20,288,000	30,389,000	46,690,000	35,120,000	27,514,000	31,143,000	31,172,000	27,356,000	15,807,000	16,533,000	34,550,000	27,398,000																																											0.00%	0.00%
basic net income per common share	330	190	290	450	340	270	300	310	270	150	150	320	260																		870	120	110
diluted net income per common share	290	170	250	410	320	250	280	280	250	140	140	300	240																		790	110	100																							-188,493,000	-188,493,000
weighted-average shares outstanding used in computing net income per common share																																																								6,824,000	6,824,000
basic	104,111,000	104,106,000	103,232,000	103,371,000	103,118,000	102,791,000	103,560,000	102,014,000	101,964,000	107,885,000	106,787,000	107,125,000	106,289,000	106,012	115,653	115,791	116,294	116,818	115,412	115,734	115,006	114,575	114,349	113,875	114,340	114,844		115,798	115,492	114,882	113,527	113,603	113,249	112,867	110,566	110,652	110,034
diluted	120,485,000	119,819,000	113,480,000	113,723,000	111,244,000	109,915,000	111,742,000	111,099,000	109,590,000	115,425,000	115,966,000	116,620,000	115,399,000	115,037	125,963	125,136	126,680	129,668	124,194	124,464	123,234	122,226	122,566	121,762	121,783	123,895		126,159	127,515	127,733	124,515	125,651	123,011	121,189	116,139	116,419	115,329
income tax expense			-1,214,000	-5,730,000	-6,108,000	-7,231,000			-5,402,000	-2,555,000			-4,650,000		20,305,000	-5,833,000	-5,530,000		46,369,000	-3,716,000	-7,945,000	-9,117,000	-3,854,000	-8,012,000	-5,625,000	-1,779,000			-3,000,000	-3,830,000
other comprehensive income:
unrealized loss on available-for-sale investments, net of tax effect of 323 and 61, respectively														-1,019,000
foreign currency translation gain, net of tax														-105,000	14,000	-77,000	16,000	26,000
total comprehensive income														21,673,000	31,711,000	30,371,000	26,489,000	23,299,000	25,832,000	21,362,000	28,857,000	30,114,000	29,328,000	26,333,000	20,413,000	18,438,000	13,331,250	17,797,000	18,221,000	17,307,000	98,269,000	13,760,000	12,642,000	4,376,000
basic net income per share														0.22	0.28	0.26	0.23	0.2	0.22	0.19	0.25	0.26	0.25	0.23	0.18	0.16	0.115	0.15	0.16	0.15
diluted net income per share														0.2	0.26	0.24	0.21	0.18	0.2	0.17	0.23	0.25	0.24	0.22	0.17	0.15	0.105	0.14	0.14	0.14
weighted-average shares outstanding used in computing net income per share
basic	104,111,000	104,106,000	103,232,000	103,371,000	103,118,000	102,791,000	103,560,000	102,014,000	101,964,000	107,885,000	106,787,000	107,125,000	106,289,000	106,012	115,653	115,791	116,294	116,818	115,412	115,734	115,006	114,575	114,349	113,875	114,340	114,844		115,798	115,492	114,882	113,527	113,603	113,249	112,867	110,566	110,652	110,034
diluted	120,485,000	119,819,000	113,480,000	113,723,000	111,244,000	109,915,000	111,742,000	111,099,000	109,590,000	115,425,000	115,966,000	116,620,000	115,399,000	115,037	125,963	125,136	126,680	129,668	124,194	124,464	123,234	122,226	122,566	121,762	121,783	123,895		126,159	127,515	127,733	124,515	125,651	123,011	121,189	116,139	116,419	115,329
net unrealized gain on available-for-sale investments, net of tax effect of 8, 109, 85 and (81), respectively															-66,250	-23,000
net unrealized gain on available-for-sale investments, net of tax effect of 16, (170), 77 and (190), respectively																	-50,000
net unrealized gain on available-for-sale investments, net of tax effect of 61 and (20), respectively																		-192,000
net unrealized gain on available-for-sale investments, net of tax impact of 109, 1, (81) and (123), respectively																			64,750	-347,000
foreign currency translation loss, net of tax																			14,250	84,000	-15,000	-12,000	-1,250	-5,000
net unrealized gain on available-for-sale investments, net of tax impact of (170), (73), (190) and (124), respectively																					545,000
net unrealized gain on available-for-sale investments, net of tax impact of (20) and (52), respectively																						61,000
net unrealized income on available-for-sale investments, net of tax impact of 1, (16), (123) and 25, respectively																							97,250	-2,000
net unrealized income on available-for-sale investments, net of tax impact of (73), , (124) and 41, respectively																									227,000
net unrealized income on available-for-sale investments, net of tax impact of (52) and 48, respectively																										164,000
net unrealized income on available-for-sale investments, net of tax impact of (16), 0, 25 and 0, respectively																											-19,250	50,000
other comprehensive loss:
net unrealized income on available-for-sale investments, net of tax impact of , 0, 41 and 0, respectively																													25,000
net unrealized loss on available-for-sale investments, net of tax impact of 48 and 0, respectively																														-152,000
net unrealized gain on available-for-sale investments																															-3,500	3,000
benefit from income taxes																																	-50,000	-127,000
net unrealized loss on available-for-sale investments																																	-5,000	-12,000
basic and diluted net income per common share																																		40	40	20	10
net income and comprehensive income																																			4,597,000	2,585,000	977,000		-1,841,750	-601,000
net income and comprehensive loss																																						-19,000			-1,936,000	-4,830,000	-6,872,000	-6,006,000	-7,552,000	-13,930,000	-11,124,000	-10,906,000	-11,897,000	-12,084,000	-11,124,000	-8,293,000	-7,597,000	-11,034,000	-6,435,000
basic and diluted net income per share																																						0	-0.018	-0.01	-0.02	-0.05	-0.068	-0.06	-0.07	-0.14	-0.11	-0.11	-0.12	-0.12	-0.11	-0.08	-0.09	-0.13	-0.08			-0.023		-0.1	-0.025	-0.1		-0.075	-0.11		-0.1	-0.01	-0.04		-0.1	-0.233	-0.28		-0.23	-0.18	-0.06	-0.24	-0.24	-0.18	-0.18	-0.28
weighted-average shares outstanding used in computing basic and diluted net income per share																																						109,661		108,461	107,874	101,905		101,134	100,980	100,521		99,814	99,814	99,814		99,082	88,621	84,420	84,188					62,655		49,763			48,754		40,235
product sales																																											9,014,000	7,282,000	5,851,000	4,405,000	4,115,000	2,634,000	1,891,000	1,717,000	1,377,000	1,055,000	875,000
other income																																																					-5,000	-5,000	-1,000			-1,627,000	-1,620,000	-11,000	-1,603,000	-2,000	-1,594,000	-623,000	-954,000	-283,000	-4,000	-270,000	-2,000	-263,000	-3,000	-242,000	-8,000	-251,000	-20,000
collaboration revenue																																																											1,014,000		1,008,000	6,000	1,014,000	919,000	66,000	776,000		402,000	374,000	776,000	108,000	73,000		221,000
research and development*																																																							3,228,000			128,587,000	123,274,000	4,489,000	110,869,000	3,342,000	110,462,000	90,383,000	3,300,000	91,783,000	2,850,000	84,497,000	1,160,000	82,985,000	1,601,000	59,885,000	5,147,000	69,728,000	4,521,000	3,325,000	52,248,000	4,714,000	4,306,513	3,098,255	2,569,419	1,576,584
general and administrative*																																																							3,209,000			47,378,000	44,208,000	1,575,000	39,216,000	1,546,000	39,348,000	30,573,000	1,668,000	31,783,000	1,233,000	28,347,000	793,000	27,393,000	1,135,000	20,373,000	1,402,000	21,730,000	960,000	1,061,000	18,159,000	1,073,000	1,215,881	1,159,711	1,125,027	993,445
* includes non-cash stock-based compensation consisting of the following:
general and administrative																																																							844			11,018	10,422	421	9,163	399	9,167	6,987	328	7,344	350	6,758	-108	6,215	221	5,001	274	5,320	180	213	4,538	253	289,664	354,803	439,992	390,490
total non-cash stock-based compensation																																																							954	-183,305,000	-183,305,000	16,451	15,823	484	14,371	467	14,378	11,798	398	12,220	414	11,446	-52	10,895	250	9,077	377	9,668	233	19	8,460	327	374,437	214,322	557,132	531,492
legal settlement																																																										187,500	750,000
*includes non-cash stock-based compensation consisting of the following:
shares used in computing basic and diluted net income per share																																																																				8,685.5	34,742		25,932	5,672.75	22,719		22,621	22,594	5,644	22,576	1,381,915	22,532,466	19,777,534	8,959,753
______________ * includes non-cash stock-based compensation expense (recovery) consisting of the following:																																																								-1,636,000	-1,636,000
_______________ *includes non-cash stock-based compensation consisting of the following:																																																								1,014,000	1,014,000
*includes non-cash stock-based compensation of the following:																																																								138,084,000	138,084,000
operating activities																																																								51,423,000	51,423,000
adjustments to reconcile net income to net cash from operations:
depreciation																																																								11,982	11,982																		4					531	531	531
amortization of deferred compensation, net of reversals																																																								17,533	17,533																		496	295	76.5	306		1,251,946	1,054,624	514,492
expense related to stock issued for services or in conjunction with license agreement																																																																											81	50	5	20
interest accrued on convertible promissory notes																																																																																10,416	10,416	5,208
changes in operating assets and liabilities:
prepaid expenses and other current assets																																																																											8	-479	10.25	41		-507,518	-713,348	-182,599
other assets																																																																											-29	-36	-1	-4		-18,695	-14,051	-13,873
accounts payable																																																																											283	-425	-66.25	-265		658,673	307,959	171,217
accrued liabilities																																																																											547	100	-75.25	-301		-38,666	78,619	-185,636
net cash from operating activities																																																																											-13,456	-10,118	-1,428.75	-5,715		-8,815,748	-5,375,920	-2,224,589
investing activities
purchases of property and equipment																																																																											-59	-51
purchases of short-term and long-term investments																																																																											-21,120	-13,531	-2,374.75	-9,499
maturities of short-term investments																																																																											30,071	20,585					1,504,823	1,504,823
net cash from investing activities																																																																											8,892	7,003	821.5	3,286		-28,259,045	-18,487,293	1,504,823
financing activities
proceeds from issuance of common stock, net of cash paid for issuance costs																																																																											1	1				49,025,252	49,025,252
proceeds from issuance of convertible preferred stock, net of cash paid for issuance costs
proceeds from issuance of convertible notes payable
proceeds from repayment of stockholder notes
proceeds from issuance of capital leases, net of short-term portion																																																																											45	10
net cash from financing activities																																																																											46	11				49,025,252	49,025,252	-360,000
net increase in cash and cash equivalents																																																																											-4,518	-3,104	-607.25	-2,429		11,950,459	25,162,039	-1,079,766
cash and cash equivalents, at beginning of period																																																																											5,930	5,930	1,482.5	5,930
cash and cash equivalents, at end of period																																																																											1,412	2,826	875.25	3,501
non-operating expense																																																																												-7,000	-2,000	-8,000
maturities of short-term and long-term investments																																																																													3,196.25	12,785
proceeds from issuance of convertible notes
interest expense																																																																															-2,604		-5,208	-5,208
* includes non-cash stock-based compensation expense (credits) of the following
expense related to stock issued for services
expense related to stock issued in conjunction with license agreement
expense related to stock issued below fair value																																																																																51,000	34,000	17,000
purchases of investments																																																																																-31,713,868
maturities of investments																																																																																3,454,823
proceeds from issuance of convertible note payable
proceeds from issuance of convertible promissory notes
proceeds from repayment of stockholder note
payment to repurchase common stock
cash and cash equivalents at beginning of period																																																																																10,073,103	10,073,103	10,073,103
cash and cash equivalents at end of period																																																																																22,023,562	35,235,142	8,993,337
supplemental disclosure of non-cash financing activities:
conversion of convertible promissory notes and accrued interest
to common stock																																																																																534,105
to convertible preferred stock
* includes non-cash stock-based compensation expense (credits) of the following:
purchases of short-term investments																																																																																	-19,992,116
* includes non-cash stock-based compensation of the following:
payment of issuance costs related to initial public offering																																																																																		-360,000
proceeds from issuance of common stock

We provide you with 20 years income statements for Corcept Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Corcept Therapeutics stock. Explore the full financial landscape of Corcept Therapeutics stock with our expertly curated income statements.

The information provided in this report about Corcept Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.